CLRB
Cellectar Biosciences, Inc.
Price Chart
Latest Quote
$2.79
+0.31 (+12.50%)
Current Price
| Previous Close | $2.48 |
| Open | $2.48 |
| Day High | $2.92 |
| Day Low | $2.46 |
| Volume | 292,688 |
Stock Information
| Shares Outstanding | 7.99M |
| Total Debt | $1.53M |
| Cash Equivalents | $8.35M |
| Net Income | $-20.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.30M |
| EPS (TTM) | $-5.38 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.66M |
| Income | $-20.84M |
| Book/sh | $0.66 |
| Cash/sh | $1.04 |
| Employees | 11 |
Financial Ratios
| Quick Ratio | 1.71 |
| Current Ratio | 1.90 |
| Debt/Eq | 32.41 |
Returns & Margins
| ROA | -102.96% |
| ROE | -290.42% |
Ownership
| Insider Ownership | 2.07% |
| Institutional Ownership | 16.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.74 |
| P/B | 4.20 |
Analyst Data
| Recommendation | none |
| Target Price | $10.33 |
Technical Indicators
| SMA20 | $2.71 |
| SMA50 | $2.84 |
| SMA200 | $3.47 |
| RSI | 40.11 |
| ATR | 0.2186 |
| Shares Float | 7.82M |
| Short Float | 3.24% |
| Short Ratio | 0.09 |
| Volatility | 0.54 |
| Rel Volume | 1.73 |
Performance History
| Week | +24.00% |
| Month | -8.82% |
| Quarter | -12.26% |
| 6 Months | -12.26% |
| YTD | -19.60% |
| Year | -73.43% |
| 3 Years | -94.80% |
| 5 Years | -99.34% |
| 10 Years | -99.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $2.79 | 299,500 |
| 2026-06-17 | $2.48 | 101,000 |
| 2026-06-16 | $2.45 | 298,800 |
| 2026-06-15 | $2.34 | 167,400 |
| 2026-06-12 | $2.23 | 66,100 |
| 2026-06-11 | $2.25 | 53,500 |
| 2026-06-10 | $2.26 | 111,900 |
| 2026-06-09 | $2.36 | 192,700 |
| 2026-06-08 | $2.51 | 153,300 |
| 2026-06-05 | $2.59 | 183,700 |
| 2026-06-04 | $2.75 | 137,100 |
| 2026-06-03 | $2.60 | 243,700 |
| 2026-06-02 | $2.74 | 241,300 |
| 2026-06-01 | $2.97 | 151,500 |
| 2026-05-29 | $3.14 | 276,800 |
| 2026-05-28 | $3.14 | 169,100 |
| 2026-05-27 | $3.14 | 144,400 |
| 2026-05-26 | $3.10 | 186,900 |
| 2026-05-22 | $3.20 | 139,500 |
| 2026-05-21 | $3.17 | 146,800 |
| 2026-05-20 | $3.17 | 314,500 |
| 2026-05-19 | $3.06 | 521,200 |
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
đ° Latest News
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2026-05-14T23:02:08ZCellectar Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T21:08:53Z
Cellectar (CLRB) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-14T18:49:13Z
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-05-07T16:00:03Z
Cellectar (CLRB) Phase 2b Data Shows Durable Responses in WaldenstrÃļm Macroglobulinemia
InvestorsHub âĸ 2026-05-05T14:21:30Z
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-04T17:32:14Z
Cellectar (CLRB) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-04T14:59:12Z
Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2025-11-13T21:00:41Z
Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma
MT Newswires âĸ 2025-10-27T13:12:40ZAll You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
Zacks âĸ 2025-07-15T16:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $22,979,844 | $51,777,698 | $38,960,643 | $28,813,773 |
| Other Income Expense | $753,707 | $6,051,399 | $-4,257,114 | $-3,191,364 |
| Net Non Operating Interest Income Expense | $435,100 | $1,210,853 | $387,147 | $152,519 |
| Operating Expense | $22,979,844 | $51,777,698 | $38,960,643 | $28,813,773 |
| General And Administrative Expense | $11,481,083 | $25,641,452 | $11,694,367 | $10,548,062 |
| Other Non Operating Income Expenses | - | $-7,743,284 | $-470,000 | $-6,824,605 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Net Interest Income | $435,100 | $1,210,853 | $387,147 | $152,519 |
| Interest Income | $435,100 | $1,210,853 | $387,147 | $152,519 |
| Normalized Income | $-22,544,744 | $-55,479,246 | $-38,988,798 | $-35,419,319 |
| Net Income From Continuing And Discontinued Operation | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Total Operating Income As Reported | $-22,979,844 | $-51,777,698 | $-38,960,643 | $-28,813,773 |
| Net Income Common Stockholders | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Net Income | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Net Income Including Noncontrolling Interests | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Net Income Continuous Operations | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Pretax Income | $-21,791,037 | $-44,515,446 | $-42,830,610 | $-31,852,618 |
| Interest Income Non Operating | $435,100 | $1,210,853 | $387,147 | $152,519 |
| Operating Income | $-22,979,844 | $-51,777,698 | $-38,960,643 | $-28,813,773 |
| Special Income Charges | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-8.35 | $-41.89 | $-105.00 | $-121.50 |
| Basic EPS | $-8.35 | $-36.52 | $-105.00 | $-121.50 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $2,896,883 | $-5,302 | $6,540 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-23,519,954 | $-65,280,728 | $-34,981,154 | $-32,298,579 |
| Total Unusual Items | $753,707 | $13,794,683 | $-3,787,114 | $3,633,241 |
| Total Unusual Items Excluding Goodwill | $753,707 | $13,794,683 | $-3,787,114 | $3,633,241 |
| Reconciled Depreciation | $213,597 | $291,653 | $192,375 | $148,435 |
| EBITDA (Bullshit earnings) | $-22,766,247 | $-51,486,045 | $-38,768,268 | $-28,665,338 |
| EBIT | $-22,979,844 | $-51,777,698 | $-38,960,643 | $-28,813,773 |
| Diluted Average Shares | $2,608,317 | $1,238,125 | $407,385 | $235,188 |
| Basic Average Shares | $2,608,317 | $1,220,749 | $407,385 | $235,188 |
| Diluted NI Availto Com Stockholders | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-31,792,618 |
| Tax Provision | $0 | $66,000 | $-60,000 | $-60,000 |
| Gain On Sale Of Security | $753,707 | $13,794,683 | $-3,787,114 | $3,633,241 |
| Research And Development | $11,498,761 | $26,136,246 | $27,266,276 | $18,265,711 |
| Selling General And Administration | $11,481,083 | $25,641,452 | $11,694,367 | $10,548,062 |
| Other Gand A | $11,481,083 | $25,641,452 | $11,694,367 | $10,548,062 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,537,164 | $14,294,681 | $-15,158,968 | $8,153,244 |
| Total Assets | $14,978,321 | $25,474,047 | $12,075,580 | $21,589,790 |
| Total Non Current Assets | $939,451 | $1,223,654 | $1,622,063 | $1,060,189 |
| Other Non Current Assets | $29,780 | $29,780 | $29,780 | $81,214 |
| Current Assets | $14,038,465 | $24,250,272 | $10,453,213 | $20,529,601 |
| Other Current Assets | $842,432 | $961,665 | $888,225 | $663,243 |
| Cash Cash Equivalents And Short Term Investments | $13,196,033 | $23,288,607 | $9,564,988 | $19,866,358 |
| Cash And Cash Equivalents | $13,196,033 | $23,288,607 | $9,564,988 | $19,866,358 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $409,586 | $494,003 | $552,982 | $603,828 |
| Long Term Debt And Capital Lease Obligation | $309,397 | $409,586 | $494,003 | $552,981 |
| Current Debt And Capital Lease Obligation | $100,189 | $84,417 | $58,979 | $50,847 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,441,157 | $11,179,366 | $27,234,548 | $13,436,546 |
| Total Non Current Liabilities Net Minority Interest | $1,691,420 | $1,791,609 | $1,876,026 | $1,935,004 |
| Current Liabilities | $4,749,737 | $9,387,757 | $25,358,522 | $11,501,542 |
| Other Current Liabilities | $225,548 | $1,718,340 | $16,120,543 | $5,972,695 |
| Payables And Accrued Expenses | $3,334,000 | $6,974,000 | $7,110,000 | $4,562,000 |
| Payables | $1,441,000 | $4,105,000 | $5,620,000 | $2,558,000 |
| Accounts Payable | $1,441,000 | $4,105,000 | $5,620,000 | $2,558,000 |
| Equity | ||||
| Common Stock Equity | $8,016,386 | $13,773,903 | $-19,836,600 | $8,153,244 |
| Preferred Stock Equity | $520,778 | $520,778 | $4,677,632 | $1,382,023 |
| Total Equity Gross Minority Interest | $8,537,164 | $14,294,681 | $-15,158,968 | $8,153,244 |
| Stockholders Equity | $8,537,164 | $14,294,681 | $-15,158,968 | $8,153,244 |
| Retained Earnings | $-269,133,500 | $-247,342,463 | $-202,761,017 | $-159,990,407 |
| Preferred Securities Outside Stock Equity | $1,382,023 | $1,382,023 | $1,382,023 | $1,382,023 |
| Other | ||||
| Ordinary Shares Number | $4,240,129 | $1,535,995 | $691,470 | $312,842 |
| Share Issued | $4,240,129 | $1,535,995 | $691,470 | $312,842 |
| Tangible Book Value | $8,016,386 | $13,773,903 | $-19,836,600 | $8,153,244 |
| Invested Capital | $8,016,386 | $13,773,903 | $-19,836,600 | $8,153,244 |
| Working Capital | $9,288,728 | $14,862,515 | $-14,905,309 | $9,028,059 |
| Capital Lease Obligations | $409,586 | $494,003 | $552,982 | $603,828 |
| Total Capitalization | $8,537,164 | $14,294,681 | $-15,158,968 | $8,153,244 |
| Additional Paid In Capital | $277,149,844 | $261,116,351 | $182,924,210 | $168,143,557 |
| Capital Stock | $520,820 | $520,793 | $4,677,839 | $94 |
| Common Stock | $42 | $15 | $207 | $94 |
| Preferred Stock | $520,778 | $520,778 | $4,677,632 | $0 |
| Long Term Capital Lease Obligation | $309,397 | $409,586 | $494,003 | $552,981 |
| Current Capital Lease Obligation | $100,189 | $84,417 | $58,979 | $50,847 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,090,000 | $611,000 | $2,069,000 | $916,000 |
| Current Accrued Expenses | $1,893,000 | $2,869,000 | $1,490,000 | $2,004,000 |
| Net PPE | $909,671 | $1,193,874 | $1,592,283 | $978,975 |
| Accumulated Depreciation | $-1,186,000 | $-1,024,000 | $-885,000 | $-692,534 |
| Gross PPE | $2,095,671 | $2,217,874 | $2,477,283 | $1,671,509 |
| Leases | $310,000 | $310,000 | $310,000 | $309,897 |
| Other Properties | $360,671 | $436,874 | $502,283 | $560,334 |
| Machinery Furniture Equipment | $1,425,000 | $1,471,000 | $1,665,000 | $801,278 |
| Properties | $0 | $0 | $0 | $0 |
| Preferred Shares Number | - | - | - | $204 |
| Buildings And Improvements | - | - | - | $560,334 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-23,124,097 | $-47,687,196 | $-33,241,012 | $-25,448,272 |
| Operating Activities | ||||
| Operating Cash Flow | $-23,118,217 | $-47,583,001 | $-32,376,974 | $-25,222,301 |
| Cash Flow From Continuing Operating Activities | $-23,118,217 | $-47,583,001 | $-32,376,974 | $-25,222,301 |
| Operating Gains Losses | $-753,707 | $-5,905,673 | $4,257,114 | $3,386 |
| Investing Activities | ||||
| Capital Expenditure | $-5,880 | $-104,195 | $-864,038 | $-225,971 |
| Investing Cash Flow | $-5,880 | $-104,195 | $-864,038 | $-225,971 |
| Cash Flow From Continuing Investing Activities | $-5,880 | $-104,195 | $-864,038 | $-225,971 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,788,380 | $0 | $22,150,000 | $9,610,655 |
| Financing Cash Flow | $13,031,523 | $61,410,815 | $22,939,642 | $9,610,655 |
| Cash Flow From Continuing Financing Activities | $13,031,523 | $61,410,815 | $22,939,642 | $9,610,655 |
| Net Common Stock Issuance | $5,788,380 | $0 | - | $9,610,655 |
| Common Stock Issuance | $5,788,380 | $0 | - | $9,610,655 |
| Net Preferred Stock Issuance | - | $0 | $22,150,000 | $9,610,655 |
| Preferred Stock Issuance | - | $0 | $22,150,000 | $9,610,655 |
| Other | ||||
| End Cash Position | $13,196,033 | $23,288,607 | $9,564,988 | $19,866,358 |
| Beginning Cash Position | $23,288,607 | $9,564,988 | $19,866,358 | $35,703,975 |
| Changes In Cash | $-10,092,574 | $13,723,619 | $-10,301,370 | $-15,837,617 |
| Proceeds From Stock Option Exercised | $7,243,143 | $61,410,815 | $789,642 | $0 |
| Net PPE Purchase And Sale | $-5,880 | $-104,195 | $-864,038 | $-225,971 |
| Purchase Of PPE | $-5,880 | $-104,195 | $-864,038 | $-225,971 |
| Change In Working Capital | $-3,126,976 | $-1,725,724 | $3,475,808 | $1,683,736 |
| Change In Other Current Liabilities | $-84,417 | $-58,979 | $-50,846 | $-144,035 |
| Change In Payables And Accrued Expense | $-3,161,792 | $-1,593,305 | $3,700,202 | $1,623,529 |
| Change In Prepaid Assets | $119,233 | $-73,440 | $-173,548 | $204,242 |
| Other Non Cash Items | $76,202 | $65,409 | $58,051 | $90,432 |
| Stock Based Compensation | $2,263,704 | $4,272,780 | $2,410,288 | $1,452,964 |
| Depreciation Amortization Depletion | $213,597 | $291,653 | $192,375 | $148,435 |
| Depreciation And Amortization | $213,597 | $291,653 | $192,375 | $148,435 |
| Gain Loss On Investment Securities | $-753,707 | $-6,051,399 | $4,257,114 | - |
| Net Income From Continuing Operations | $-21,791,037 | $-44,581,446 | $-42,770,610 | $-28,601,254 |
| Gain Loss On Sale Of PPE | - | - | $0 | $3,386 |
| Issuance Of Debt | - | - | - | - |
| Interest Paid Supplemental Data | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-17